Valeant Pharmaceuticals Intl Inc Wells Fargo analyst David Maris weighs in on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), as the drug maker focuses …
Sarepta Therapeutics Inc (NASDAQ:SRPT) granted equity awards on November 30, 2016, that were previously approved by the Compensation Committee of its Board of …
By Brett Eversole U.S.
Sarepta Therapeutics Inc (NASDAQ:SRPT) reported financial results for the three and nine months ended September 30, 2016. “We are thrilled that the first patient …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
Cowen top analyst Ritu Baral shares insight on Sarepta Therapeutics Inc (NASDAQ:SRPT) after speaking with three key opinion leaders (KOLs) regarding the recent approval …
This week, Sarepta Therapeutics Inc (NASDAQ:SRPT) dosed its first patient with commercial Exondys 51 (eteplirsen), the biotech firm’s intravenous infusion Duchenne muscular dystrophy …
Tuesday, Sarepta Therapeutics Inc (NASDAQ:SRPT) and Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) announced a deal that will grant Sarepta European commercialization rights for Summit’s …
Yesterday, Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) announced a collaboration and license agreement, which will grant Sarepta Therapeutics Inc (NASDAQ:SRPT) European Union commercialization rights …
Sarepta Therapeutics Inc (NASDAQ:SRPT) just announced two Duchenne muscular dystrophy (DMD) collaborations to evaluate combotherapy with exon skipping. Sarepta will be partering with …
